CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+11.72%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(+4.7%)
Cap. Flow
+$8.57M
Cap. Flow
% of AUM
3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
267
Reduced
44
Closed
122
Top Buys
| 1 |
iQIYI
IQ
|
$12.8M |
| 2 |
Amazon
AMZN
|
$3.31M |
| 3 |
uniQure
QURE
|
$3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.97M |
| 5 |
DexCom
DXCM
|
$2.87M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.65M |
| 2 |
Tesla
TSLA
|
$3.64M |
| 3 |
Procter & Gamble
PG
|
$3.53M |
| 4 |
Nike
NKE
|
$3.17M |
| 5 |
CVS Health
CVS
|
$2.99M |
Sector Composition
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Maravai LifeSciences
MRVI
$347M
| $19.1K | 0.01% |
1,336
+104
| +8% | +$1.49K |
|
177
Edwards Lifesciences
EW
$47.6B
| $19.1K | 0.01% |
256
| – | – |
|
178
Ventyx Biosciences
VTYX
$173M
| $18.9K | 0.01% |
+575
| New | +$18.9K |
|
179
Arvinas
ARVN
$573M
| $18.5K | 0.01% |
541
+43
| +9% | +$1.47K |
|
180
Genmab
GMAB
$15.9B
| $18.4K | 0.01% |
434
+81
| +23% | +$3.43K |
|
181
Relay Therapeutics
RLAY
$636M
| $18.3K | 0.01% |
1,228
+208
| +20% | +$3.11K |
|
182
Pacira BioSciences
PCRX
$1.2B
| $18K | 0.01% |
466
+37
| +9% | +$1.43K |
|
183
Veracyte
VCYT
$2.39B
| $17.3K | 0.01% |
729
+58
| +9% | +$1.38K |
|
184
IQVIA
IQV
$31.5B
| $17.2K | 0.01% |
84
| – | – |
|
|
KDNY
185
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $17K | 0.01% |
649
+60
| +10% | +$1.57K |
|
186
Rhythm Pharmaceuticals
RYTM
$6.95B
| $16.7K | 0.01% |
572
+97
| +20% | +$2.83K |
|
|
SWTX
187
DELISTED
SpringWorks Therapeutics
SWTX
| $16.5K | 0.01% |
634
+171
| +37% | +$4.45K |
|
|
VRNA
188
Verona Pharma
VRNA
$9.16B
| $16.1K | 0.01% |
+617
| New | +$16.1K |
|
189
Day One Biopharmaceuticals
DAWN
$781M
| $16.1K | 0.01% |
747
+59
| +9% | +$1.27K |
|
190
Xencor
XNCR
$598M
| $15.9K | 0.01% |
609
+50
| +9% | +$1.3K |
|
191
Agios Pharmaceuticals
AGIO
$2.23B
| $15.7K | 0.01% |
558
+45
| +9% | +$1.26K |
|
192
Syndax Pharmaceuticals
SNDX
$1.44B
| $15.6K | 0.01% |
612
+82
| +15% | +$2.09K |
|
|
RVNC
193
DELISTED
Revance Therapeutics, Inc.
RVNC
| $15.4K | 0.01% |
836
+152
| +22% | +$2.81K |
|
194
Nuvalent
NUVL
$5.6B
| $15.4K | 0.01% |
518
+115
| +29% | +$3.43K |
|
195
FibroGen
FGEN
$44.7M
| $15.3K | 0.01% |
955
+77
| +9% | +$1.23K |
|
|
DICE
196
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $15.1K | 0.01% |
+484
| New | +$15.1K |
|
197
Rocket Pharmaceuticals
RCKT
$360M
| $15K | 0.01% |
769
+151
| +24% | +$2.96K |
|
198
Immunocore
IMCR
$1.66B
| $15K | 0.01% |
+262
| New | +$15K |
|
199
Recursion Pharmaceuticals
RXRX
$2.05B
| $14.2K | 0.01% |
1,846
+299
| +19% | +$2.31K |
|
200
MannKind Corp
MNKD
$1.84B
| $14.1K | 0.01% |
2,674
+264
| +11% | +$1.39K |
|